These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 323459)

  • 1. Effect of active drug metabolites on plasma level-response correlations.
    Atkinson AJ; Strong JM
    J Pharmacokinet Biopharm; 1977 Apr; 5(2):95-109. PubMed ID: 323459
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of active metabolites on monitoring plasma concentrations of therapeutic drugs.
    Atkinson AJ; Stec GP; Lertora JJ; Ruo TI; Thenot JP
    Ther Drug Monit; 1980; 2(1):19-27. PubMed ID: 6762700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of therapeutic agents in blood.
    Marks V; Lindup WE; Baylis EM
    Adv Clin Chem; 1973; 16():47-109. PubMed ID: 4589494
    [No Abstract]   [Full Text] [Related]  

  • 4. Determination of plasma procainamide and N-acetylprocainamide concentration by high-pressure liquid chromatography.
    Dutcher JS; Strong JM
    Clin Chem; 1977 Jul; 23(7):1318-20. PubMed ID: 872378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacology of cardio-active agents.
    Hayes AH
    Cardiovasc Clin; 1972; 4(3):103-18. PubMed ID: 4130206
    [No Abstract]   [Full Text] [Related]  

  • 6. Glutethimide and 4-OH glutethimide: pharmacokinetics and effect on performance in man.
    Crow JW; Lain P; Bochner F; Shoeman DW; Azarnoff DL
    Clin Pharmacol Ther; 1977 Oct; 22(4):458-64. PubMed ID: 902458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration.
    Chiou WL; Lam G; Chen ML; Lee MG
    Res Commun Chem Pathol Pharmacol; 1981 Apr; 32(1):27-39. PubMed ID: 7291727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic and pharmacokinetic measurements in cardiovascular-renal drugs.
    Hayes AH
    Clin Pharmacol Ther; 1974 Jul; 16(1):201-11. PubMed ID: 4843316
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: Limitations in the use of hydrolytic rate constants for the simultaneous determination of drug and metabolite in serum.
    Fung HL
    Biochem Med; 1974 Feb; 9(2):190-2. PubMed ID: 4822039
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical pharmacokinetics of procainamide.
    Karlsson E
    Clin Pharmacokinet; 1978; 3(2):97-107. PubMed ID: 346289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical pharmacology of antiarrhythmic drugs. Part 1: Lidocaine and procainamide.
    Levitt B; Borer JS; Sarapa A
    Cardiovasc Nurs; 1974; 10(5):23-6. PubMed ID: 4498548
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiarrhythmic structure activity relationships in a series of lidocaine procainamide derivatives.
    Ehring GR; Hondeghem LM
    Proc West Pharmacol Soc; 1981; 24():221-4. PubMed ID: 7255453
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum drug concentrations in clinical perspective.
    Koch-Weser J
    Ther Drug Monit; 1981; 3(1):3-16. PubMed ID: 7015580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new method for constant plasma drug concentrations: application to lidocaine.
    Riddell JG; McAllister CB; Wilkinson GR; Wood AJ; Roden DM
    Ann Intern Med; 1984 Jan; 100(1):25-8. PubMed ID: 6691655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial kidneys and clearance calculations.
    Gibson TP; Matusik E; Nelson LD; Briggs WA
    Clin Pharmacol Ther; 1976 Dec; 20(6):720-6. PubMed ID: 991541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procainamide and the sinus node.
    Dhingra RC; Rosen KM
    Chest; 1979 Dec; 76(6):620-1. PubMed ID: 509999
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma drug levels as an aid to medical treatment.
    Fitzgerald DJ; O'Malley K
    Ir Med J; 1984 Jan; 77(1):23-6. PubMed ID: 6363342
    [No Abstract]   [Full Text] [Related]  

  • 18. General derivation of the ideal intravenous drug input required to achieve and maintain a constant plasma drug concentration. Theoretical application to lignocaine therapy.
    Vaughan DP; Tucker GT
    Eur J Clin Pharmacol; 1976; 10(6):433-40. PubMed ID: 1001359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function.
    Drayer DE; Lowenthal DT; Woosley RL; Nies AS; Schwartz A; Reidenberg MM
    Clin Pharmacol Ther; 1977 Jul; 22(1):63-9. PubMed ID: 872496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural simularities and cardiac electrophysiological differences between lidocaine and procainamide.
    Ehring GR; Hondeghem LM
    Proc West Pharmacol Soc; 1980; 23():163-6. PubMed ID: 7403120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.